Skip to main content
PLOS One logoLink to PLOS One
. 2022 Feb 28;17(2):e0263692. doi: 10.1371/journal.pone.0263692

Sex-specific and concentration-dependent influence of Cremophor RH 40 on ampicillin absorption via its effect on intestinal membrane transporters in rats

Heyue Yin 1,, Haibin Shao 1,#, Jing Liu 1,#, Yujia Qin 1,#, Wenbin Deng 1,*
Editor: Chun-Hua Wang2
PMCID: PMC8884507  PMID: 35226682

Abstract

Pharmaceutical excipients are the basic materials and important components of pharmaceutical preparations, and play an important role in improving the efficacy of drugs and reducing adverse reactions. Therefore, selecting suitable excipients for dosage form is an important step in formulation development. An increasing number of studies have revealed that the traditionally regarded "inert" excipients can, however, influence the bioavailability of drugs. Moreover, these effects on the bioavailability of drugs caused by pharmaceutical excipients may differ in between males and females. In this study, the in situ effect of the widely-used pharmaceutical excipient Cremophor RH 40 spanning from 0.001% to 0.1% on the intestinal absorption of ampicillin in male and female rats using closed-loop models was investigated. Cremophor RH 40 ranging from 0.03% to 0.07% increased the absorption of ampicillin in females, however, was decreased in male rats. The mechanism of such an effect on drug absorption is suggested to be due to the interaction between Cremophor RH 40 and two main membrane transporters P-gp and PepT1. Cremophor RH 40 altered the PepT1 protein content in a sex-dependent manner, showing an increase in female rats but a decrease in males. No modification on the PepT1 mRNA abundance was found with Cremophor RH 40, indicating that the excipient may regulate the protein recruitment of the plasma membrane from the preformed cytoplasm pool to alter the PepT1 function. This influence, however, may differ between males and females. As such, the study herein shows that supposedly inert excipient Cremophor RH 40 can influence membrane fluidity, uptake and efflux transporters in a sex- and concentration-dependent manner. These findings, therefore, highlight the need for sex-specific studies in the application of solubilizing excipients in drug formulation development.

Introduction

Oral absorption is a complex process determined by the interplay of physiological and biochemical processes, physicochemical properties of the active pharmaceutical ingredients (APIs), formulation factors and physiological characteristics of the gastrointestinal tract. Intestinal membrane transporters have also been shown to play an essential role in drug absorption [1]. The extraction of chemicals from the intestinal lumen is achieved by passive diffusion which is also accomplished by a variety of uptake transporters. Likewise, there are apical efflux transporters on enterocytes that prevent the entry of chemicals into the systemic circulation and are often responsible for the poor oral bioavailability of pharmaceuticals. To modify drug absorption, therefore, some relative activators and/or inhibitors are co-formulated with the active pharmaceutical ingredient (API).

Emerging research has demonstrated that allegedly ‘inert’ excipients are capable of modulating the membrane transporters which can consequently result to enhanced or reduced drug absorption. For instance, polyethylene glycol (PEG), hydroxypropyl-beta-cyclodextrin (HPCD), vitamin E TPGS, DM-β-CyD and Cremophor EL cause pharmacological effect and exhibit substantial interactions with a number of intestinal uptake transporters including organic anion transporting polypeptide (OATPs) [2] and efflux transporters P-glycoprotein (P-gp), multidrug resistant-associated protein 2 (Mrp2) [37]. However, limited knowledge and understanding is known regarding the sex differences of these interactions.

The sex-specific influence of excipients on drug bioavailability was first recognized following the study on the widely-used solubilizing agent, PEG 400, where low concentrations of PEG 400 were found to increase the absorption of ranitidine in men but not in women [8]. Interestingly, the sex-related influence of PEG 400 only occurred for drugs whose absorption is controlled by the P-gp efflux transporter such ranitidine and ampicillin in an animal model established for this investigation [9]. It is highly suggested that the sex-based differences in the interaction between PEG 400 and P-gp demonstrates a greater influence in male rats when compared with females [10, 11]. In addition to PEG 400, a portfolio of solubilizing agents such as Cremophor RH 40, Poloxamer 188 and Tween 80 have exhibited a sex-specific reduction on the activity and expression of efflux transporter P-gp to increase the permeability and absorption of P-gp-mediated drug ranitidine [12]. Specifically, Cremophor RH 40 showed the opposite effect on ranitidine intestinal permeability in male and female rats via the Using chamber system [12]. Cremophor RH 40 (macrogolglycerol hydroxystearate polyoxyl 40 hydrogenated castor oil) is a condensation of hydrogenated castor oil with ethylene oxide, which is soluble in most organic solvents, water is dispersed, with excellent emulsification, diffusion properties. Therefore, it has been widely used as a non-ionic solubilizer and emulsifying agent in formulation development.

Moreover, in a previous study on Caco-2 cell lines, the inhibitory influence of Cremophor RH 40 ranging from 0.001% to 3% on P-gp enhanced with the increase of its concentration, with 100% blocking of P-gp by 3% Cremophor RH 40 [13]. Based on this, the effect of excipients on transporters are not only sex-dependent but also dose-dependent.

On the other hand, the underlying mechanism behind this sex-based phenomenon is unclear although a number of hypothesis are possible. The inhibitory on P-gp function could be attributed to downregulation of P-gp expression, inhibition of P-gp ATPase, depletion of intracellular ATP, changes on related nuclear receptors or alteration in membrane fluidity. Thus, to further investigate the reason behind the sex-dependent effect of excipients on the P-gp, the modification on these factors (especially intestinal membrane fluidity) with Cremophor RH 40 in different concentrations will be studied in this work. To determine whether Cremophor RH 40 could alter the function of other main intestinal membrane transporter, such as oligopeptide transporter 1 (PepT1) and Mrp2, the influence of Cremophor RH 40 on the absorption of ampicillin (the substrate of PepT1, P-gp and Mrp2) was also examined using an in situ closed-loop animal model. Finally, the protein and mRNA expressions of these three transporters (PepT1, P-gp and Mrp2) were quantitated in male and female rats with/without the addition of Cremophor RH 40.

Materials and methods

Reagents and materials

Ampicillin sodium was purchased from Bide Pharmatech Ltd. (Shanghai, China). Cremophor RH 40 was purchased from Meilun Biotechnology Company Ltd. (Dalian, China). HEPES, Tris, and EGTA, mannitol, glucose were supplied by Sigma-Aldrich. (USA). Tma-DPH was supplied by BestBio. (Shanghai, China). Water and acetonitrile were purchased from Fisher Scientific (Loughborough, UK) and were of HPLC grade. All other chemicals and kits are noted individually in the following methods.

Preparation and solubility measurement of solutions

Ampicillin sodium was dissolved in phosphate buffered saline (PBS) at pH 7.4 to yield a final dose of 5 mg/kg in the absence or presence of Cremophor RH 40 (0.001%–0.1%, w/v).

In order to determine the saturated solubility of ampicillin in different Cremophor RH 40 solutions, samples were prepared by adding an excess amount of compound to different Cremophor RH 40 solutions in vials of 10 mL. The vials were kept under stirring at 100 rpm and controlled temperature at 37°C (±0.1°C). The solubility of ranitidine in the different solutions was: 0 g Cremophor RH 40 (410 mg/ml); 0.001% Cremophor RH 40 (417 mg/ml); 0.01% Cremophor RH 40 (409 mg/ml); 0.03% Cremophor RH 40 (400 mg/ml); 0.05% Cremophor RH 40 (421 mg/ml); 0.07% Cremophor RH 40 (424 mg/ml); 0.1% Cremophor RH 40 (414 mg/ml).

Animals

Animals used for the experiments were male and female Wistar rats (8 weeks old, 24 males and 24 female rats in total) purchased from the Southern Medical University Laboratory Animal Centre (Guangzhou, China). Male and female Wistar rats weighed approximately 300 g and 250 g respectively. The animal protocol was approved by the Sun Yat-sen University Animal Use and Care Committee (SYSU-IACUC-2021-000319).

Influence of cremophor RH 40 on ampicillin absorption

In situ closed-loop model set-up

Animal work for screening the potential sex-effect of Cremophor RH 40 from 0.001% to 0.1% concentrations were performed at the Sun Yat-sen University Laboratory Animal Centre. The protocol was agreed by the Administrative Committee on Animal Research in Sun Yat-sen University. All rats were housed at room temperature (25°C) and in a light-dark cycle of 12 h. The rats were caged in groups of 4, allowed to move freely and provided with food and water before the experiment. The day before the experiment, the rats were fasted overnight and individually housed in metabolic cages.

On the day of the experiment, each rat was weighed and anesthetized with Somnopentyl® (sodium pentobarbital, 32 mg/kg body weight intraperitoneally). The intestine was exposed through midline abdominal incision. After ligating the bile duct, a segment of jejunum (about 20 cm long) was isolated and washed with PBS and then tied off at both ends to form a closed loop. The drug solution was warmed to 37°C and 3 mL was injected into the jejunum loop. Subsequently, approximately 250 μL–300 μL of blood was collected from the rats’ tail vein and transferred to anticoagulant centrifuge tubes (BD Microtainer® K2E Becton, Dickinson and Company, USA) at predetermined time intervals up to 240 min. At the end of the experiment, the luminal solution was collected to measure the remaining ampicillin, the amount of protein released and the activity of lactate dehydrogenase (LDH). Also, the jejunum loop tissues were kept at -80°C until use.

Preparation of blood samples

Blood samples were centrifuged at 10,000 rpm for 10 min and the supernatants (plasma samples) were collected into 1.5 mL Eppendorf tubes, the same volume of methanol was added to precipitate the plasma proteins. After 1 min of vortex-mixing, the mixture was centrifuged at 4°C for 10 min at 10,000 rpm. The supernatant was collected and 50 μL aqueous was analysed by HPLC.

HPLC analysis

Chromatographic analysis was performed with a HPLC system (Waters Breeze) equipped with Binary HPLC pump (Waters 1525), autosampler (Waters 2707) and an UV/Visible detector (Waters 2489). The drug was quantified by HPLC using a Luna C18 (250 mm × 4.6 mm I.D./5 μm) column (FLM, Guangzhou, China) using 10 mM sodium dihydrogen phosphate buffer (pH 7.0)- methanol (60:40, v/v). The flow rate was 1 mL/min, and the UV detector was set at 220 nm.

Pharmacokinetic analysis

Pharmacokinetic parameters (Cmax, tmax, AUC0-240 and AUC) were calculated by non-compartmental analyses using a free Microsoft Excel add-in “PKSolver.”

Effect of cremophor RH 40 on intestinal membrane damage

The release of protein and the activity of LDH in small intestinal membranes were used to evaluate small intestinal membrane damage in the presence of Cremophor RH 40 using an in situ closed-loop method. Triton X-100 (3%, v/v) were selected as the positive control in this study by being administered into the intestinal loop. The collected luminal solution was washed with PBS for the determination of the amount of protein released and the activity of LDH. The concentrations of protein released from the intestinal membranes were measured with BSA as a standard using the BCA Assay Protein kit (Beyotime Biotechnology, Shanghai, China). The activities of LDH were determined using the LDH CII Assay Kit according to the manufacturer’s instructions.

Measurement of PepT1, P-gp and Mrp2 protein levels in rat intestine by ELISA

The in situ jejunal loop after experiments was excised and washed with cold PBS. To obtain the mucosal tissue, 5 cm tissues were placed on an ice-cold glass plate and the serosa layer was gently squeezed out with a cover slip, following divided into aliquots for determination of P-gp protein content.

The mucosal tissues (about 50 mg) of the intestinal of rats were cut into small pieces and homogenized in 0.5 ml RIPA lysis buffer at 30 Hz for 30 s with a TissueLyser (QIAGEN, Hilden, Germany), and repeated twice at intervals of 30s to completely homogenized. The tissue homogenates were incubated at 4°C for 2h, then centrifuged at 4°C, 12,000 g for 5 min. The total tissue protein was collected in the supernatants, and its concentration was subsequently determined with the BCA Assay Protein kit (Beyotime Biotechnology, Shanghai, China) according to the manufacturer’s instructions. To measure the targeted transporter protein levels, PepT1, P-gp and MRP2 was quantified by ELISA kits (Meimian Biotech, Yancheng, China) based on the manufacturer’s description.

Measurement of PepT1, P-gp and Mrp2 mRNA expression in intestinal segments by real time reverse-transcription polymerase chain reaction (RT-PCR)

Total RNA in each intestinal sample was isolated and purified with Tissue RNA Purification Kit Plus (ESscience Biotech, Shanghai, China), and RNA concentration was measured with Nanodrop 2000 (Thermofisher) according to the manufacturer’s instructions.

Subsequently, the quantification of the target RNA was conducted as follows; 0.5 μg total RNA of each sample was reverse transcribed using the Fast Reverse Transcription Master Mix (Aivd Biotech, Shenzhen, China). To quantify the amount of PepT1 mRNA, P-gp mRNA (mdr1a and mdr1b) and mrp2 mRNA, RT-PCR was performed on the LightCycler® 96 (Roche, Basel, Switzerland) using the method described in MacLean’s study [14]. Briefly, 20 μL PCR reaction contained 10 μL of AB-HS SYBR Green qPCR Mix (Aivd Biotech), 2 μL each of forward and reverse primers, and 2 μL of cDNA, and 4 μL ddH2O. RT-PCR was carried out in 96 well PCR plates (Thermofisher). The amplification program for all genes consisted of one pre-incubation cycle at 95°C with a 2 min hold, followed by 45 amplification cycles with denaturation at 95°C with a 10s hold, an annealing temperature of 60°C with a 20 s hold, and an extension at 72°C with a 15 s hold. Amplification was followed by a melting curve analysis, which ran for one cycle with denaturation at 95°C with a 1 s hold, annealing at 65°C with a 15 s hold, and melting at 95°C with a 1 s hold. Distilled water was included as a negative control in each run to access specificity of primers and possible contaminants.

Primers (shown in Table 1) were designed by primer-BLAST searching with publicly available sequence information of the Gene Bank of the National Center for Biotechnology Information (NCBI) and purchased from TSINGKE (Beijing, China). Relative expression of PepT1, mdr1a, mdr1b and mrp2 mRNA in the intestinal was calculated using LightCycler® 96 software (version 1.1, Roche). The average of the threshold cycle (Ct) values for tested genes (PepT1, mdr1a, mdr1b and mrp2) and the internal control (anti-beta actin) was taken, and then the differences between Ct values for tested genes and internal control (ΔCt) were calculated for all the experimental samples.

Table 1. Primers used for the analysis of P-gp and PepT1 gene expression by RT-PCR.

Gene Primer (5′– 3′) Amplicon (bp)
mdr1a Forward 5′-CACCA TCCAGAACGCAGACT-3′ 139
Reverse 5′-ACATCTCGCATGGTCACAGTT-3′
mdr1b Forward 5′-AACGCAGACTTGATCGTGGT-3′ 144
Reverse 5′-AGCACCTCAAATACTCCCAGC-3
rPept1 Forward 5′-GTATGTTCTGTTCGCCTCCTTG-3′ 228
Reverse 5′-GGTGAATGCTGGACTTGGTATG-3′
anti-beta actin Forward 5′-GCAGGAGTACGATGAGTCCG-3′ 74
Reverse 5′-ACGCAGCTCAGTAACAGTCC-3′

Effect of cremophor RH 40 on intestinal membrane fluidity

Preparation of the rat intestinal brush border membrane vesicles

Brush border membrane vesicles (BBMVs) were prepared by the divalent cation precipitation method using MgCl2 in the presence of ethylenebis (oxyethylenenitrilo) tetraacetic acid (EGTA), as described previously. In brief, an 5 cm in situ small intestinal loop in male and female Wistar rats was excised and divided into segments, and the mucosa was scraped with a slide glass and homogenized in 10 volumes of buffer (5 mM EGTA, 12 mM Tris, 300 mM mannitol; pH 7.4 by 1 M 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES)) with a TissueLyser (QIAGEN, Hilden, Germany). A stock solution of 1 M MgCl2 was added to the homogenate to give a final concentration of 10 mM MgCl2. The mixture was gently stirred for 1 min and allowed to stand at 4ºC for 15 min. Then, the suspension was centrifuged at 3000 g for 15 min. The pellets were discarded, and the supernatant was centrifuged again at 32,000 g for 30 min. The pellets containing BBMVs were resuspended by 27-gauge needle in the homogenizing buffer. The protein concentrations were determined by BCA Assay Protein kit (Beyotime Biotechnology, Shanghai, China) using BSA as a standard, and the final concentration was adjusted to 1 mg/mL in each tube. The samples were frozen by liquid N2 and kept at -80ºC until use.

Measurement of membrane fluidity by fluorescence polarization

Fluorescence polarization techniques were used to evaluate the effects of Cremophor RH 40 on small intestinal membrane fluidity using the fluorescence probes Tma-DPH. BBMV suspensions (protein concentration, 100 mg/mL) were incubated with 0.5 μM Tma-DPH for 5 min in Tris-HEPES buffer (25 mM HEPES, 5 mM glucose, 140 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 0.8 mM MgSO4; pH 7.4 with 1 M Tris). 200 mM cholesterol as a positive control was added. Then, the fluorescence intensities and steady-state polarization were determined using a Hitachi F2000 spectrophotometer (Hitachi, Yokohama, Japan) equipped with a polarizer set. The fluorescence polarization (ℑ) was calculated following Eq 1:

=(I||G·I)/(I||+G·2·I) (1)

where I|| and I represent the fluorescent intensities of the parallel and perpendicular polarized excitation, respectively. G is the equipment parameter. The excitation and emission wavelengths were 360 nm and 430 nm, respectively, for Tma-DPH.

Statistical analysis

All results are expressed as mean ± SD (n = 4). The control and test group data were analysed by one-way ANOVA followed by post-hoc Tukey analysis with a 95% confidence interval using IBM SPSS Statistics 16 (SPSS Inc., Illinois, USA).

Results

The intestinal absorption of 5mg/kg ampicillin in the absence of excipients presented by the cumulative area under the plasma concentration versus time curve (AUC0-240min) in male and female rats was 4693 ± 1652 μg.min/mL and 786 ± 189 μg.min/mL respectively, described in Fig 1a. As shown in Fig 1b, the plasma concentrations of ampicillin were markedly different in male and female rats. And the effect of Cremophor RH 40 on the pharmacokinetic parameters of ampicillin in male and female Wistar rats is shown in S1 Table. In terms of the membrane transporters, significant higher PepT1, Mrp2 and P-gp protein levels were found in male rats compared with the female groups (shown in Fig 1c, 1e and 1g). P-gp related mdr1a mRNA expression also showed a sex-specific difference indicating higher abundance in males (Fig 1d), while mdr1b contents were similar in both sexes. As found in Fig 1f and 1h, Mrp2 and rPept1 mRNA expression was consistent with its protein levels, revealing a slightly higher content in the jejunum of male group.

Fig 1. Related pharmacokinetic parameters and intestinal membrane transporter expression in male and female Wistar rats.

Fig 1

(a) the absorption (AUC0–240min) of 5mg/kg ampicillin; (b) plasma concentration-time profile of ampicillin; (c) P-gp protein abundance; (d) mdr1a mRNA expression; (e) Mrp2 protein content; (f) Mrp2 mRNA level; (g) PepT1 protein expression; (h) rPepT1 level. All the data were expressed as mean ± standard error of at least 4 experiments. * Values are statistically different between the male and female groups.

Assays for LDH and the release of protein were conducted to measure membrane damage by Cremophor RH 40 in the small intestine by an in situ closed-loop experiment. The results showed the activity of LDH and the amount of protein released were not significantly different compared with the control.

The presence of 0.03% to 0.07% Cremophor RH 40 excipient concentrations significantly increased the intestinal absorption of ampicillin in female rats by 41%, 32% and 25% respectively (p < 0.05). However, in their male counterparts, ampicillin bioavailability reductions were observed with Cremophor RH 40 in these doses (0.03%, 0.05% and 0.07%) indicating a 17%, 32% and 20% decrease over the control (p < 0.05) (Fig 2).

Fig 2. Percentage change in the absorption (AUC0–240min) of ampicillin (5 mg/kg) in the presence of Cremophor RH 40 in the jejunum of male and female Wistar rats by an in situ closed-loop study (mean ± SD, n = 4).

Fig 2

* Values are statistically different between the control (i.e. no Cremophor RH 40) and the Cremophor RH 40 groups at p < 0.05.

With regards to the P-gp protein and gene abundance, Cremophor RH 40 ranging from 0.001% to 0.05% had no influences on the P-gp levels (protein and mdr1a) in neither male rats nor females. However, 0.07% and 0.1% Cremophor RH 40 decreased its expression in males, while no alteration was observed in their female counterparts (Figs 3 and 4). It can also be seen from S1 Fig, the intestinal mdr1b expression in both males and females fluctuated with Cremophor Rh 40 dose, and no trend could be observed. Thus, a strong positive correlation between mdr1a (but not mdr1b) expression and P-gp protein abundance, with high levels of P-gp protein associated with high levels of mdr1a expression.

Fig 3. Percentage change in P-gp protein level in the presence of Cremophor RH 40 in the jejunum of male and female Wistar rats (mean ± SD, n = 4).

Fig 3

* Values are statistically different between the control (i.e. no Cremophor RH 40) and the Cremophor RH 40 groups at p < 0.05.

Fig 4. Percentage change in mdr1a mRNA expression in the presence of Cremophor RH 40 in the jejunum of male and female Wistar rats (mean ± SD, n = 4).

Fig 4

* Values are statistically different between the control (i.e. no Cremophor RH 40) and the Cremophor RH 40 groups at p < 0.05.

From S2 Fig, the Mrp2 protein expression was not altered with the addition of Cremophor RH 40 in different concentrations in neither male nor female rats (p > 0.05), which also indicated no sex differences on the effect of excipients on the function of Mrp2.

In relation to the uptake transporter Pept1 (obtained in Fig 5), the presence of 0.03% to 0.07% concentrations of Cremophor RH 40 enhanced the protein abundance by 48%, 36% and 23% in female rats. Although an enhancement in PepT1 protein level was achieved with 0.1% Cremophor RH 40 in female rats, this result was not statistically significant (p > 0.05). However, Cremophor RH 40 reduced the protein content in male rats, the greatest reduction of 29% was demonstrated in the presence of 0.1% Cremophor RH 40 when compared with the control (p < 0.05). Moreover, the presence of Cremophor RH 40 was not able to alter the Pept1 mRNA expression in both male and female rats, and this was not a clear trend (present in Fig 6).

Fig 5. Percentage change in PepT1 protein level in the presence of Cremophor RH 40 in the jejunum of male and female Wistar rats (mean ± SD, n = 4).

Fig 5

* Values are statistically different between the control (i.e. no Cremophor RH 40) and the Cremophor RH 40 groups at p < 0.05.

Fig 6. Percentage change in rPepT1 mRNA expression in the presence of Cremophor RH 40 in the jejunum of male and female Wistar rats (mean ± SD, n = 4).

Fig 6

No significant differences were observed (p > 0.05).

To elucidate the mechanisms of transporter alteration by Cremophor RH 40 in different concentrations, intestinal membrane fluidity was measured by fluorescence polarization. The polarization of Tma-DPH fluorescence probes was significantly decreased in males but not in female rats by the addition of higher concentrations (0.07% and 0.1%, w/v) of Cremophor RH 40, compared with that of control group (shown in Fig 7).

Fig 7. Influences of Cremophor RH 40 ranging from 0.001% to 0.1% on BBMVs intestinal membrane fluidity of the male and female Wistar rats (mean ± SD, n = 12), present by fluorescence anisotropy of the intestinal membrane labeled with Tma-DPH as a probe.

Fig 7

* Values are statistically different between the control (i.e. no Cremophor RH 40) and the Cremophor RH 40 groups at p < 0.05.

Discussion

The values of ampicillin in vivo bioavailability were not consistent with the results reported in previous study [9] where drug absorption was higher in female rats, compared with the males. The intestinal absorption of ampicillin obtained using in situ closed-loop rat model in the present study was, however, 5-fold higher in male rats than females. This may be explained by the different ampicillin dosages, routes of administration, experimental models and the period of pharmacokinetic studies. To be specific, the transit time differed between males and females which has been excluded in the in situ closed-loop rat model study [15]. Also, the exposure areas of intestine to drug solution was much larger in the in vivo rat study than that during the in situ mode. All these differences between these two experiments might lead to the variations.

As the substrate of intestinal membrane transporter PepT1, P-gp and Mrp2, ampicillin absorption was related to the abundance of these proteins [1618]. There were a few studies that reported sex-related differences in the expression of uptake transporter PepT1 in the intestine, PepT1 mRNA was once reportedly highly expressed in small intestine compared with other organs and no significant difference between sexes in Sprague-Dawley rats and C57BL/6 mice [19]. However, based on the results herein, female Wistar rats demonstrated a higher PepT1 regardless of protein and gene expression, which also well supported the in situ intestinal absorption data. On the other hand, higher P-gp expression in male rats than females was in agreement with values reported in the previous literature [10, 11]. Surprisingly, higher P-gp should result in lower ampicillin absorption in males compared with female rats, the opposite findings would be attributed to the larger influences of intestinal PepT1 levels, which suggested the oral absorption of ampicillin was mainly influenced by the uptake transporter, PepT1, in both male and female rats. In terms of Mrp2, our findings were also fully supported by an earlier work where demonstrated no significant differences in Mrp2 protein and mRNA expression between males and females in the rodents’ intestine [14].

The alteration on ampicillin intestinal absorption with excipients, however, was demonstrated in a concentration- and sex-dependent manner. Although the bioavailability of a drug is influenced by many factors, the solubility of ampicillin was specifically measured and Cremophor RH 40 from 0.01% to 0.1% had no statistically significant effect (p > 0.05) on the solubility of ampicillin, thereby eliminating it as a reason for any observed increases in drug absorption.

Cremophor RH 40 is frequently used as a solubilizing enhancer in the oral formulations. Recent research, however, have reported its inhibitory effect on P-gp to enhance the drug permeability at a dose higher than its critical micelle concentration (CMC) [12]. In this study, the modification on ampicillin absorption by Cremophor RH 40 was, however, resulted from the sex-dependent influences on two membrane transporters mentioned above, P-gp and PepT1. No significant alteration was observed on the efflux transporter Mrp2 by the addition of Cremophor RH 40.

On the one hand, regarding the P-gp efflux transporter, our results demonstrate the influence of Cremophor RH 40 at lower doses showed no effects on P-gp protein levels in rats while higher concentrations (0.07% and 0.1%) displayed a P-gp inhibitory, reflecting similar findings to previous investigations; in a study by Wandel et al., the effects of low concentrations of Cremophor RH 40 (0.001% to 3%) as potential P-gp inhibitors were tested with the use of digoxin transport in Caco-2 cells. The results showed that the increase in Cremophor RH 40 concentration inhibited P-gp efflux transporter ability at a greater extent and achieving complete P-gp inhibition following the administration of 3% Cremophor RH 40 [13]. However, there is limited knowledge and understanding in the effect of Cremophor RH 40 on P-gp expression in females. A clear statistical contrast to that seen in male rats (p < 0.05) was observed in our study. Specifically, in females, the intestinal P-gp abundance was not influenced in the presence of Cremophor RH 40 in all the tested concentrations (ranging from 0.001% to 0.1%). The reason behind this sex-related influence of excipients on efflux transporter P-gp was yet unknown.

Alternatively, it is possible that Cremophor RH 40 may cause the intestinal membrane damage and enhance intestinal absorption of P-gp substrates. However, Cremophor RH 40 in all tested doses had no effect on the activities of LDH and the amount of protein compared to the control group. Thus, Cremophor RH 40 at a low concentration could be considered to be safe P-gp modulators to increase the intestinal absorption of P-gp substrates via reducing the P-gp expression in males. Moreover, P-gp is reportedly sensitive to the lipid environment and might be involved in lipid trafficking and metabolism [20]. Our findings indicated that Cremophor RH 40 at 0.07% and 0.1% concentrations might increase the membrane fluidity of lipid bilayers and the protein portion of the membrane in male rats but not female, especially the fluidity of the hydrophobic core of the outer lipid bilayers, because the maximal reducing effect was observed in the fluorescence polarization of Tma-DPH, which probes the fluidity of the polar head group region of the outer lipid bilayer [21]. This also, in the first time, suggested the sex-dependent influence of ‘inert’ pharmaceutical excipients on the intestine membrane fluidity.

On the other hand, the expression and function of the influx transporter PepT1 can be modulated by numerous factor, such as substrates, proteins, hormones and diseases status [22]. In present study, intestinal PepT1 protein expression was first reported to be regulated by excipient Cremophor RH 40, even in a dose- and sex-based manner. Based on the previous literatures, alteration on the function of PepT1 protein were conducted via two mechanisms. One is a long-term modification, which is influenced by the transcriptional and/or post-transcriptional status. For example, 1 day of fasting could increase the population of Pept-1 in the brush-border membrane of rat intestine via mediation on peroxisome proliferator-activated receptor α (PPARα) to induce dipeptide transport, which was considered in the transcriptional level [23, 24]. The post-transcriptional regulation of PepT1 caused by the postsynaptic density-95/disk-large/ZO-1 [PDZ] domain-containing protein (PDZK1) was first identified in 2008 [25]. In this study, a significant decrease in the PepT1’s location at the apical membrane of small intestinal epithelial cells was found in PDZK1 gene knockout mice. However, insulin and leptin were involved in the regulation of PepT1 even with different molecular mechanism, which were short-term action. Thamotharan et al. hardly ever discovered changes in the PepT1 mRNA level in Caco-2 cells incubating with insulin, while the protein level of PepT1 in the apical membrane was increased [26, 27]. Following this, they proposed that insulin may regulate PepT1 via increasing the protein recruitment of the plasma membrane from the preformed cytoplasm pool. That is to say, although insulin cannot be found in the gut lumen, the peptide transport activity still can be regulated by binding to its receptor located in the basolateral membrane of the intestinal mucosal cells [28]. Moreover, leptin increased the membrane PepT1 protein, decreased intracellular PepT1 content, however, showed no effects in rPepT1 mRNA levels [29]. The findings in our study indicating that Cremophor RH 40 regulated the PepT1 protein abundance but not mRNA level was similar to the insulin- and leptin-induced work. Therefore, Cremophor RH 40 may modify the protein recruitment of the plasma membrane from the preformed cytoplasm pool to alter the PepT1 function, and this modification might differ between males and females.

To our knowledge, mammals absorb various substrates in the gastrointestinal tract through PepT1, the regulation of PepT1 has implications in studies of enteral nutrition and especially drug therapy [22]. The sex-dependent effect of pharmaceutical excipients Cremophor RH 40 on the PepT1 function, for the first time, was reported in this study. The mechanism behind this sex-specific phenomenon was still unknown. However, the usage of personalized cell model (such as intestinal organoid, intestine-on-a-chip) [3032], in-depth study of the 3D structure and factors affecting PepT1 activity and mechanisms of action can better provide information to investigate the reason underlying this sex-based influence of excipients on the PepT1 expression.

Great progress has been made in the application of excipients in formulation development, not only for predetermined purposes but to actively modulate drug bioavailability according to the work reported here. The co-formulation of pharmaceutically relevant excipient concentrations of Cremophor RH 40 was able to actively modulate the enhancement of ampicillin permeability and intestinal PepT1 expression, however, this was limited to male and not female rats. The sex differences demonstrated by this study highlights the need for the screening of “inert” pharmaceutical excipients in terms of their selection and use for oral drug development, particularly for PepT1 substrates, in order to negate potential adverse events from an increase in bioavailability or from the lack of therapeutic effect. Also, the application of these sex-specific excipients in oral formulation developments could lead to a ‘sex-related’ formulation and/or personalized formulation field, resulting in better therapeutic efficacy and lower side effects, and supporting precision medicine.

Supporting information

S1 Fig. Percentage change in mdr1b mRNA expression in the presence of cremophor RH 40 in the jejunum of male and female Wistar rats (mean ± SD, n = 4).

(TIF)

S2 Fig. Mrp2 protein level in the presence of cremophor RH 40 in the jejunum of male and female Wistar rats measured by ELISA (mean ± SD, n = 4).

(TIF)

S1 Table. Effect of Cremophor RH 40 on the pharmacokinetic parameters of ampicillin in male and female Wistar rats (mean±standard deviation, n = 4).

(DOCX)

S1 Graphical abstract

(JPEG)

Acknowledgments

We are grateful to Dr. Mai Y. for her advice and guidance on the subject. We also thank the scientific research platform provided by Sun Yat-Sen University for the smooth progress of our experiments.

Data Availability

All relevant data are within the manuscript and its Supporting information files.

Funding Statement

Dr. Wenbin Deng received the awards and this work was supported by the financial support from the Shenzhen Science and Technology Program (Grant No. KQTD20190929173853397), and the National Natural Science Foundation of China (Grant No. 81772449 and 81971081). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Zhang L., Elmer L.W., and Little K.Y., Expression and regulation of the human dopamine transporter in a neuronal cell line. Brain Res Mol Brain Res, 1998. 59(1): p. 66–73. doi: 10.1016/s0169-328x(98)00138-7 [DOI] [PubMed] [Google Scholar]
  • 2.Engel A., et al., Pharmaceutical Excipients Influence the Function of Human Uptake Transporting Proteins. Molecular Pharmaceutics, 2012. 9(9): p. 2577–2581. doi: 10.1021/mp3001815 [DOI] [PubMed] [Google Scholar]
  • 3.Dintaman J.M. and Silverman J.A., Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharmaceutical Research, 1999. 16(10): p. 1550–1556. doi: 10.1023/a:1015000503629 [DOI] [PubMed] [Google Scholar]
  • 4.Yunomae K., et al., Involvement of cholesterol in the inhibitory effect of dimethyl-beta-cyclodextrin on P-glycoprotein and MRP2 function in Caco-2 cells. Febs Letters, 2003. 536(1–3): p. 225–231. doi: 10.1016/s0014-5793(03)00059-0 [DOI] [PubMed] [Google Scholar]
  • 5.Sachs-Barrable K., et al., Lipid Excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of Rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 Cells. Journal of Pharmacy and Pharmaceutical Sciences, 2007. 10(3): p. 319–331. [PubMed] [Google Scholar]
  • 6.Mohammadzadeh R., et al., Reduced ABCB1 Expression and Activity in the Presence of Acrylic Copolymers. Adv Pharm Bull, 2014. 4(3): p. 219–24. doi: 10.5681/apb.2014.032 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Hodaei D., et al., Effects of polyethylene glycols on intestinal efflux pump expression and activity in Caco-2 cells. Brazilian Journal of Pharmaceutical Sciences, 2015. 51(3): p. 745–753. [Google Scholar]
  • 8.Ashiru D.A., Patel R., and Basit A.W., Polyethylene glycol 400 enhances the bioavailability of a BCS class III drug (ranitidine) in male subjects but not females. Pharm Res, 2008. 25(10): p. 2327–33. doi: 10.1007/s11095-008-9635-y [DOI] [PubMed] [Google Scholar]
  • 9.Mai Y., et al., Excipient-mediated alteration in drug bioavailability in the rat depends on the sex of the animal. Eur J Pharm Sci, 2017. 107: p. 249–255. doi: 10.1016/j.ejps.2017.07.009 [DOI] [PubMed] [Google Scholar]
  • 10.Mai Y., et al., An animal’s sex influences the effects of the excipient PEG 400 on the intestinal P-gp protein and mRNA levels, which has implications for oral drug absorption. Eur J Pharm Sci, 2018. doi: 10.1016/j.ejps.2018.04.021 [DOI] [PubMed] [Google Scholar]
  • 11.Mai Y., et al., Establishing an in vitro permeation model to predict the in vivo sex-related influence of PEG 400 on oral drug absorption. Int J Pharm, 2018. 542(1–2): p. 280–287. doi: 10.1016/j.ijpharm.2018.03.002 [DOI] [PubMed] [Google Scholar]
  • 12.Mai Y., et al., Sex-Dependence in the Effect of Pharmaceutical Excipients: Polyoxyethylated Solubilising Excipients Increase Oral Drug Bioavailability in Male but not Female Rats. Pharmaceutics, 2019. 11(5). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Wandel C., Kim R.B., and Stein C.M., "Inactive" excipients such as Cremophor can affect in vivo drug disposition. Clin Pharmacol Ther, 2003. 73(5): p. 394–6. doi: 10.1016/s0009-9236(03)00010-9 [DOI] [PubMed] [Google Scholar]
  • 14.MacLean C., et al., Closing the gaps: A full scan of the intestinal expression of P-glycoprotein, breast cancer resistance protein, and multidrug resistance-associated protein 2 in male and female rats. Drug Metabolism and Disposition, 2008. 36(7): p. 1249–1254. doi: 10.1124/dmd.108.020859 [DOI] [PubMed] [Google Scholar]
  • 15.Freire A.C., et al., Does sex matter? The influence of gender on gastrointestinal physiology and drug delivery. Int J Pharm, 2011. 415(1–2): p. 15–28. doi: 10.1016/j.ijpharm.2011.04.069 [DOI] [PubMed] [Google Scholar]
  • 16.Bourdet D.L. and Thakker D.R., Saturable absorptive transport of the hydrophilic organic cation ranitidine in caco-2 cells: Role of pH-Dependent organic cation uptake system and p-glycoprotein. Pharmaceutical Research, 2006. 23(6): p. 1165–1177. doi: 10.1007/s11095-006-0251-4 [DOI] [PubMed] [Google Scholar]
  • 17.Siarheyeva A., Lopez J.J., and Glaubitz C., Localization of multidrug transporter substrates within model membranes. Biochemistry, 2006. 45(19): p. 6203–6211. doi: 10.1021/bi0524870 [DOI] [PubMed] [Google Scholar]
  • 18.Konig J., Muller F., and Fromm M.F., Transporters and Drug-Drug Interactions: Important Determinants of Drug Disposition and Effects. Pharmacological Reviews, 2013. 65(3): p. 944–966. doi: 10.1124/pr.113.007518 [DOI] [PubMed] [Google Scholar]
  • 19.Lu H. and Klaassen C., Tissue distribution and thyroid hormone regulation of Pept1 and Pept2 mRNA in rodents. Peptides, 2006. 27(4): p. 850–857. doi: 10.1016/j.peptides.2005.08.012 [DOI] [PubMed] [Google Scholar]
  • 20.Ferte J., Analysis of the tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane. European Journal of Biochemistry, 2000. 267(2): p. 277–294. doi: 10.1046/j.1432-1327.2000.01046.x [DOI] [PubMed] [Google Scholar]
  • 21.Rege B.D., Kao J.P.Y., and Polli J.E., Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. European Journal of Pharmaceutical Sciences, 2002. 16(4–5): p. 237–246. doi: 10.1016/s0928-0987(02)00055-6 [DOI] [PubMed] [Google Scholar]
  • 22.Wang C.Y., et al., Regulation profile of the intestinal peptide transporter 1 (PepT1). Drug Design Development and Therapy, 2017. 11: p. 3511–3517. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Thamotharan M., et al., Functional and molecular expression of intestinal oligopeptide transporter (Pept-1) after a brief fast. Metabolism-Clinical and Experimental, 1999. 48(6): p. 681–684. doi: 10.1016/s0026-0495(99)90164-6 [DOI] [PubMed] [Google Scholar]
  • 24.Shimakura J., et al., Induction of intestinal peptide transporter 1 expression during fasting is mediated via peroxisome proliferator-activated receptor alpha. American Journal of Physiology-Gastrointestinal and Liver Physiology, 2006. 291(5): p. G851–G856. doi: 10.1152/ajpgi.00171.2006 [DOI] [PubMed] [Google Scholar]
  • 25.Sugiura T., et al., PDZK1 regulates two intestinal solute carriers (Slc15a1 and Slc22a5) in mice. Drug Metabolism and Disposition, 2008. 36(6): p. 1181–1188. doi: 10.1124/dmd.107.020321 [DOI] [PubMed] [Google Scholar]
  • 26.Thamotharan M., et al., Hormonal regulation of oligopeptide transporter Pept-1 in a human intestinal cell line. American Journal of Physiology-Cell Physiology, 1999. 276(4): p. C821–C826. [DOI] [PubMed] [Google Scholar]
  • 27.Watanabe K., et al., Effect of insulin on cephalexin uptake and transepithelial transport in the human intestinal cell line Caco-2. European Journal of Pharmaceutical Sciences, 2004. 21(1): p. 87–95. doi: 10.1016/j.ejps.2003.10.002 [DOI] [PubMed] [Google Scholar]
  • 28.Gangopadhyay A., Thamotharan M., and Adibi S.A., Regulation of oligopeptide transporter (Pept-1) in experimental diabetes. American Journal of Physiology-Gastrointestinal and Liver Physiology, 2002. 283(1): p. G133–G138. doi: 10.1152/ajpgi.00445.2001 [DOI] [PubMed] [Google Scholar]
  • 29.Buyse M., et al., PepT1-mediated epithelial transport of dipeptides and cephalexin is enhanced by luminal leptin in the small intestine. Journal of Clinical Investigation, 2001. 108(10): p. 1483–1494. doi: 10.1172/JCI13219 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Pocock K., et al., Intestine-on-a-Chip Microfluidic Model for Efficient in Vitro Screening of Oral Chemotherapeutic Uptake. Acs Biomaterials Science & Engineering, 2017. 3(6): p. 951–959. doi: 10.1021/acsbiomaterials.7b00023 [DOI] [PubMed] [Google Scholar]
  • 31.Zhao J.F., et al., A Novel Model of P-Glycoprotein Inhibitor Screening Using Human Small Intestinal Organoids. Basic & Clinical Pharmacology & Toxicology, 2017. 120(3): p. 250–255. doi: 10.1111/bcpt.12680 [DOI] [PubMed] [Google Scholar]
  • 32.Kasendra M., et al., Development of a primary human Small Intestine-on-a-Chip using biopsy-derived organoids. Scientific Reports, 2018. 8. doi: 10.1038/s41598-018-21201-7 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Chun-Hua Wang

22 Dec 2021

PONE-D-21-36367Sex-specific and concentration-dependent influence of Cremophor RH 40 on ampicillin absorption via its effect on intestinal membrane transportersPLOS ONE

Dear Dr. Deng,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Feb 05 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Chun-Hua Wang

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

3. Thank you for stating the following in the Acknowledgments Section of your manuscript: 

"We are grateful to Dr. Yang Mai for her advice and guidance on the subject.. We also thank the scientific research platform provided by Sun Yat-Sen University for the smooth progress of our experiments. This work was supported by the financial support from the Shenzhen Science and Technology Program (Grant No. KQTD20190929173853397), and the National Natural Science Foundation of China (Grant No. 81772449 and 81971081)."

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. 

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: 

"Dr. Wenbin Deng received the awards and this work was supported by the financial support from the Shenzhen Science and Technology Program (Grant No. KQTD20190929173853397), and the National Natural Science Foundation of China (Grant No. 81772449 and 81971081).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

4. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript. 

5. Please include a copy of Table 1 which you refer to in your text on page 10.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

Reviewer #4: Yes

Reviewer #5: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

Reviewer #4: I Don't Know

Reviewer #5: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: No

Reviewer #4: Yes

Reviewer #5: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

Reviewer #4: Yes

Reviewer #5: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The topic is so interesting and the research findings are well presented. Authors had discussed their results appropriately and had selected good references to support it.

The only remark is that the resolution of Figure 1 needs improvement because it is not readable.

Reviewer #2: Line 71-73 Cite a reference number for this statement.

101 Define what is PBS

104-107 Provide the number of male rats and the number of female rats used for the study separately. In the section 2.3.

127 Define what is LHD

143 According to the manuscript pharmacokinetic parameters of Cmax, tmax, AUC0-240 and AUC∞ have been calculated. However, in the results section all these parameters except AUC0-240 have to be deduced by the reader from the Figure 1b. It is required to provide the results for these parameters with the Figure 1b or separately.

145 Describe the positive and negative controls used in determining the effect of cremophor RH 40 on intestinal membrane damage.

164 Remove “a” before at

181 Provide the reference number for MacLean's study here

241-242 It is not clear the shown plasma concentration values are corresponding to what inlet concentration/s of ampicillin. Provide this information both in the paragraph here and in Figure 1b

255-257 Rather than given a range of 0.03% - 0.07%, provide the 3 Cremophor RH 40 concentrations resulting 41%, 32% and 25% increase in ampicillin absorption

310-312 If this hypothesis of possible influence of PepT1 is used to explain ampicillin absorption in male rats, how the same argument to be used to explain same thing in female. Need a discussion with respect to female rats on the same line.

318-321 Solubility measurements done is not mentioned in the methodology and in the results section. Therefore, bringing a new result in the discussion is not acceptable. Include solubility measurement method and results in the relevant sections.

Figures Poor contrasting and clarity. Need improvements

Figure 1 Write the units of the y-axis

Reviewer #3: The authors delivered a considerable work of the sex-specific and concentration-dependent influence of Cremophor RH 40 on ampicillin absorption. This work revealed the mechanisms of Cremophor RH 40 on intestinal membrane transporters to some extent, and supplied some valuable experience to evaluate the use of Cremophor RH 40 in the design and development of oral delivery systems.

However, there are still some aspects to discuss.

1. It seems irrational or inexactly that the dose of Cremophor RH 40 in the experiment was noted as volume in volume, since Cremophor RH 40 as a semi-solid excipient at room temperature, cannot be exactly measured by volume even at heated status. Also the weight dose of ingredients administrated orally was preferred rather than volume.

2. According to the results of AUC and Cmax after oral administration of 50mg/kg ampicillin mentioned in reference 9, the AUC and Cmax herein were 5-fold higher in male rats after 5mg/kg ampicillin injected into jejunum closed-loop (one tenth of the dose in reference 9). Explanations with more details should be available in line 299 of the manuscript.

3. The pharmacokinetic parameters (Cmax, tmax, AUC0-240 and AUC∞) calculated in section 2.4.4, should be listed as a table form in the manuscript.

4. Some spelling mistakes should be well corrected in line 92,164,267, etc.

Reviewer #4: The research presented in the work “Sex-specific and concentration-dependent influence of Cremophor RH 40 on ampicillin absorption via its effect on intestinal membrane transporters” is an interesting topic in relation to the most widely used excipient Cremophor RH 40 which is an important component of most pharmaceutical preparations.

The following are specific comments, questions and suggestions to improve the quality of the manuscript:

1. Since the focus of the manuscript was to find the effect of the widely-used pharmaceutical excipient Cremophor RH 40 on the intestinal absorption of ampicillin in male and female rats. Therefore, the title must express the true content of the paper and include the animal that the sex specific is related to, so I suggest addition the of the word (in rats) at the end of the title.

2. The introduction to the work was presented correctly, the only point is that no information was given regarding the excipient Cremophor RH 40, I suggest to add a small paragraph about this excipient and its physicochemical properties in the introduction part.

3. Why Cremophor RH 40 has been choose and not Cremophor EL as an excipient? did the second excipient also have the same effect on intestinal absorption of ampicillins?

4. The selection of methods is rather broad and cover the design-space well as were the reported research results.

5. the following used abbreviations should be defined:

P6 - L 101: PBS

P7 - L 127: LDH

P11- L 208: HEPES

P 12 - L 221: Tma-DPH

P 16 -L 325: CMC

Reviewer #5: The manuscript titled “Sex-specific and concentration-dependent influence of Cremophor RH 40 on ampicillin absorption via its effect on intestinal membrane transporters” reported the effects of Cremophor RH 40 on PepT1 protein recruitment on the membrane and led to the changes of ampicillin absorption in rats, which is interesting and new. The paper could even increase in quality by performing the following amendments:

1. Please explain the basis of the Cremophor RH 40 dosage used in the article and its relationship with the clinical preparations

2. transport experiments on Caco-2 cells are needed to verify the effects of Cremophor RH 40 on the PepT1 protein recruitment on the cell membrane

3. relevant references are missing in line 366

4. try to calculate/estimate the meaning of the interaction of Cremophor RH 40 and ampicillin observed in your experiments. Does the magnitude of interaction and doses reflect the clinical observations in literature? Or is it x-fold lower

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Associate Professor/ Sally A. El-Zahaby, phD

Reviewer #2: Yes: Dr. Dhanusha Thambavita

Reviewer #3: No

Reviewer #4: Yes: Shahla S. Smail

Reviewer #5: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: Comments.docx

PLoS One. 2022 Feb 28;17(2):e0263692. doi: 10.1371/journal.pone.0263692.r002

Author response to Decision Letter 0


22 Jan 2022

Dear Professor Wang,

We wish to thank the reviewer for their insightful comments.

We have amended the manuscript in accordance with the comments of the referee and provide attached a point-by-point response to the issues raised.

We have marked all the changes made in the revised manuscript.

Thank you for your time, and I look forward to hearing from you.

Yours sincerely,

Wenbin Deng

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Chun-Hua Wang

25 Jan 2022

Sex-specific and concentration-dependent influence of Cremophor RH 40 on ampicillin absorption via its effect on intestinal membrane transporters in rats

PONE-D-21-36367R1

Dear Dr. Deng,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Chun-Hua Wang

Academic Editor

PLOS ONE

Acceptance letter

Chun-Hua Wang

18 Feb 2022

PONE-D-21-36367R1

Sex-specific and concentration-dependent influence of Cremophor RH 40 on ampicillin absorption via its effect on intestinal membrane transporters in rats

Dear Dr. Deng:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Chun-Hua Wang

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Percentage change in mdr1b mRNA expression in the presence of cremophor RH 40 in the jejunum of male and female Wistar rats (mean ± SD, n = 4).

    (TIF)

    S2 Fig. Mrp2 protein level in the presence of cremophor RH 40 in the jejunum of male and female Wistar rats measured by ELISA (mean ± SD, n = 4).

    (TIF)

    S1 Table. Effect of Cremophor RH 40 on the pharmacokinetic parameters of ampicillin in male and female Wistar rats (mean±standard deviation, n = 4).

    (DOCX)

    S1 Graphical abstract

    (JPEG)

    Attachment

    Submitted filename: Comments.docx

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES